Diagnostic Use of PCR in Carbapenamase-producing Enterobacteriaceae (CPE): An Improved Method to Overcome the presence of inhibitors for DNA Extraction from Blood Cultures

Zeti Norfidiyati Salmuna¹, M.Path., Murnihayati Hassan¹, M.D.

¹Department of Microbiology, Universiti Sains Malaysia, Kelantan, Malaysia.

Corresponding Author: Zeti Norfidiyati Salmuna, MPath, Department of Medical Microbiology and Parasitology, School of Medical Sciences, University Sains Malaysia Health Campus, 16150, Kubang Kerian, Kelantan, Malaysia.

E-mail: norfidiyatiz@yahoo.com/ zetifidiyati@usm.my

Phone no: +6012-9555249/ +609-7676286 (Ext:6252). Fax number : +609-7676289.

Abstract

Background

Carbanemamase-producing Enterobacteriaceae (CPE) has emerged as a threat to hospitalized patients. Phenotypic test such as Modified hodge test was less sensitive and specific especially to detect blaNDM-1 which is the most predominant genotype in this region. Nucleic acid amplification technology offers improved specificity and sensitivity. However, there is limitation in this method which is failed amplification due to the presence of inhibitors. In this study, we try to use previous method described by Villumseen et al with some modification using another DNA extraction kit.

Methodology/Principle findings

Three confirmed isolates of blaNDM-1 carbapenamase-producing Klebsiella pneumoniae was spiked with 10 mls sterile whole blood in an aerobic Bactec Plus until the growth was detected. The blood specimen was taken and was subjected to DNA extraction method using two commercialized kits followed with multiplex PCR. All the three isolates revealed blaNDM-1 genotypes. Internal control was amplified in all three isolates.

Conclusion/significance

This study proved that we can get a specific and early diagnosis of CPE by using nucleic acid amplification technique directly from blood culture bottle and eliminate the effect of inhibitors.

Introduction

The increasing prevalence of extended spectrum beta-lactamases (ESBL) enterobacteriaceae, made carbapenem a preferred drug for treatment that results in the emergence of carbapenem-resistant Enterobacteriaceae (CRE) that has become a formidable threat to public health(28). Beside limiting treatment option, infections due to CRE are associated with higher morbidity and mortality rates (3, 23). Higher mortality rates due to carbapenemase-producing enterobacteriaceae (CPE) are multifactorial such as underlying diseases, lack of effective antimicrobials therapy and delay in starting effective antimicrobials (18).
The prevalence of CRE in South East Asia was about 2.8% as documented in one study (13). However, a study in Uganda showed that carbapenamase prevalence was 22.4% by phenotypic test, but slightly higher with the genotypic test which was 28.6% (16). However, there are limited studies regarding incidence of CRE genotype in Malaysia. One study done among 13 isolates of carbapenem-resistant *Klebsiella pneumoniae* (CRKP) in a Malaysia university hospital found that only two, *bla*NDM1 and *bla*IMP4 genotypes were detected (11).

There are mainly two different mechanisms that are responsible for carbapenem resistance in *Enterobacteriaceae* which is either ESBL or AmpC enzymes hyper production combined with porin loss or alteration or upregulated efflux pump and or production of carbapenem-hydrolyzing carbapenamases (6, 7, 20, 22, 26).

Carbapenamases are categorized into Ambler molecular classification as follows, the Class A carbapenamases (GES, KPCs) which are inhibited by clavulanic acid; the Class B or metallo-β-lactamases (VIM, IMP, NDMs) which are inhibited by ethylene diamine tetra-acetic acid (EDTA); and the Class D oxacillinases which are not affected by clavulanic acid or EDTA (8, 10, 19, 21, 27).

The most important and common cause of carbapenem resistance in CRE is due to plasmid-mediated carbapenamase production (1, 12, 21, 22, 27) that have resulted in multiple outbreaks reported from various regions of the world.

CRE is defined as *Enterobacteriaceae* that are resistant to any carbapenem antimicrobial (i.e: minimum inhibitory concentration of ≥4 mcg/ml for doripenem, meropenem or imipenem OR ≥2 mcg/ml for ertapenem) OR documented to produce carbapenamase (by MHT, Carba-NP or genotype) (4)

The Clinical and Laboratory Standard Institute (CLSI) recommended modified Hodge test (MHT), Carba-NP and genotypic test for confirmation of carbapenamase production (5). Rapid detection of this resistance mechanism is important for prescription of appropriate antimicrobial therapy and infection control measures. Although genotypic test (molecular method) is the gold standard (2), but due to budget constraint, it is only available in few reference laboratories.

Multiplex real-time PCR has proven its superiority over conventional culture and phenotypic method. A multi-centre evaluation of real-time multiplex PCR for detection of carbapenamase genes showed that the sensitivity and specificity reached 100% and it is a robust, reliable and rapid method for detection of the most prevalent carbapenamases (24). Another study showed that the overall sensitivity and specificity of multiplex PCR assay was 99% and 100% respectively (17).

Limited studies showed that direct PCR can shorten time of detection of CRE compared to culture (14). Direct PCR proved useful in outbreak settings and high prevalence areas where rapid carbapenamase detection is critical especially for infection control management (15).

In a hospital, blood cultures (BCs) are usually collected from septic patients and send before the antibiotic is given. BCs act as a close system, therefore contamination is very unlikely. However, the blood culture bottles contain inhibitors of the PCR that require
additional steps to overcome the inhibitors. Sensitivity of the assay to yield the CRE
genotypes is highly dependent on the DNA-recovery.

Sodiumpolyanetholesulfonate (SPS) that serves as an anti-coagulant in blood culture
bottle has become an inhibitor of the PCR as it tends to copurify with DNA (9). Therefore,
there are several studies done to prevent PCR inhibition. Our study is very unique as we are
able to use the previous methods and apply it with Nucleospin extraction kit. Surprisingly the
PCR was not inhibited and we are able to yield the CRE genotypes implicated in the isolates
tested.

Materials and Methods

This method was done to 3 confirmed CRE isolates (blaNDM-1 carbapenamase-
producing Klebsiella pneumoniae) labelled as A1, A2 and A3 from previous study. The
colonies were then spiked on blood culture bottles (BACTEC™ aerobic Plus) using 10 mls
sterile whole blood and incubated in BACTEC machine. After the blood culture bottle gave
the ‘beep’ sound, 100 µl of the positive blood culture specimen was then used for DNA
extraction methods.

DNA extraction methods

Method 5 (M5) DNA extraction methods that were used in previous study were used
in this study (25).

Method 1 (M1) : using DNeasy® Blood & Tissue Kit (Qiagen, Hilden, Germany)

a. Separation phase

A 100 µl aliquot of the positive blood culture specimen was mixed with 100 µl lysis
buffer [5 M UltraPure™ guanidine hydrochloride] (Invitrogen, CA) in 100 mM UltraPure™
Tris-Hcl (Ph 8.0; Invitrogen, Paisley, UK) and 10 µl proteinase K (20 mg/ml; Qiagen ) and
incubated 10 minutes at room temperature. A total of 600 ml of ultrapure water (Invitrogen)
was added followed by 800 ml 99% benzyl alcohol (Reagent Plus H, Sigma-Aldrich, Brondy,
Denmark) and mixed. In order to separate the phases, the sample was then centrifuged at
20,000 x g for 5 minutes at room temperature.

b. DNA extraction phase

The 200 µl supernatant (the aqueous phase) was then transferred to a new tube. No
proteinase K was added and the sample was not incubated during the lysis step. The final
elution step was done in 100 µl buffer AE. This method is suitable for use with all blood
culture media.

Method 2 (M2): using Nucleospin® Blood QuickPure (Macherey-Nachel, Düren,
Germany)

a. Separation phase

The method for separation phase was the same as in Method 1.

b. DNA extraction phase
The 200 µl supernatant (the aqueous phase) was then transferred to a new tube. No proteinase K was added and the sample was not incubated during the lysis step. The final elution step was done in 50 µl buffer AE.

**Experiment: Multiplex PCR**

Multiplex real-time PCR amplification for the simultaneous detection of NDM-1, VIM, IMP, OXA-48 and KPC genes are done using commercially available LightMix Modular IMP, KPC, OXA-48, VIM and NDM-1 Carbapenamase multiplex kit (by Tib Molbiol, Germany; licensed for local distribution under Roche) has been carried out on a CFX96 Touch Bio-Rad Real-Time PCR machine following the kit protocol.

Each carbapenamase gene will be detected according to target wavelength as described in the kit by the manufacturer.

**Ethical considerations**

Ethical approval was obtained from the USM Research and Ethics Committee before this study was commenced (Reference number: USM/JEPeM/16120537).

**Results**

The results for this experiment was shown in Table 1 below.

Table 1 showed the effectiveness of DNA extraction methods, M1 and M2 in recovering blaNDM-1 carbapenamase-producing *Klebsiella pneumoniae*. Both kits demonstrated amplification of internal control and multiplex PCR revealed blaNDM-1 carbapenamase-producing *Klebsiella pneumoniae*.

**Discussion**

This study has its unique feature as we are able to use the method previously described (25) and mixed it with the Method 2 by using Nucleospin® Blood QuickPure for DNA extraction from blood culture bottle. The results obtained are comparable for the three isolates. These findings showed 100% sensitivity and specificity. The first person that effectively solve the problems of inhibitors from blood cultures (BCs) were Fredrick and Relman in which they identified anti-coagulant sodium polyanetholesulfonate (SPS) presence in BCs (9). We found out that by adding Proteinase K treatment in lysis step, increasing the centrifugation speed to 20000 x g as well as adding extra water in the separation phase has solved the carry-over of inhibitors to the final DNA preparation in M2.

Currently, the diagnosis of CPE relies on phenotypic method (modified-hodge test) and Carba NP. But with these findings, it suggests that most cases of severe CPE can be diagnosed early by using PCR.

**References**

1. Bae IK, Kang HK, Jang IH, Lee W, Kim K, Kim JO, Jeong SH, Lee K. 2015. Detection of Carbapenemases in Clinical Enterobacteriaceae Isolates Using the VITEK AST-N202 Card. Infection & chemotherapy;47(3):167-74.
2. Birgy A, Bidet P, Genel N, Doit C, Decré D, Arlet G, Bingen E. 2012. Phenotypic screening of carbapenemases and associated beta-lactamases in carbapenem-resistant Enterobacteriaceae. Journal of clinical microbiology:JCM. 06131-11.

3. Carmeli Y, Akova M, Cornaglia G, Daikos GL, Garau J, Harbarth S, Rossolini GM, Souli M, Giamarellou H. 2010. Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases;16(2):102-11.

4. CDC. Facility Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE)2015.

5. CLSI. M100S Performance Standards for Antimicrobial Susceptibility testing2016 3rd August 2016.

6. Del Franco M, Paone L, Novati R, Giacomazzi CG, Bagattini M, Galotto C, Montanera PG, Triassi M, Zarrilli R. 2015. Molecular epidemiology of carbapenem resistant Enterobacteriaceae in Valle d’Aosta region, Italy, shows the emergence of KPC-2 producing Klebsiella pneumoniae clonal complex 101 (ST101 and ST1789). BMC Microbiol;15(1):015-0597.

7. Demir Y, Zer Y, Karaoglan I. 2015. Investigation of VIM, IMP, NDM-1, KPC AND OXA-48 enzymes in Enterobacteriaceae strains. Pak J Pharm Sci;28(3 Suppl):1127-33.

8. Doyle D, Peirano G, Lascols C, Lloyd T, Church DL, Pitout JD. 2012. Laboratory detection of Enterobacteriaceae that produce carbapenemases. Journal of clinical microbiology;50(12):3877-80.

9. Fredricks DN, Relman DA. 1998. Improved amplification of microbial DNA from blood cultures by removal of the PCR inhibitor sodium polyanetholesulfonate. Journal of clinical microbiology;36(10):2810-6.

10. Hammoudi D, Moubareck CA, Kanso A, Nordmann P, Sarkis DK. 2015. SURVEILLANCE of CARBAPENEM NON-SUSCEPTIBLE GRAM NEGATIVE STRAINS and CHARACTERIZATION of CARBAPENEMASES of CLASSES A, B and D in a LEBANESE HOSPITAL. Le Journal medical libanais The Lebanese medical journal;63(2):66-73.

11. Hamzan NI, Yean CY, Rahman RA, Hasan H, Rahman ZA. 2015. Detection of blaIMP4 and blaNDM1 harboring Klebsiella pneumoniae isolates in a university hospital in Malaysia. Emerg Health Threats J;8(26011).

12. Karuniawati A, Saharman YR, Lestari DC. 2013. Detection of carbapenemase encoding genes in Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumanii isolated from patients at Intensive Care Unit Cipto Mangunkusumo Hospital in 2011. Acta medica Indonesiana;45(2):101-6.

13. Kiratisin P, Chongthaleong A, Tan TY, Lagamayo E, Roberts S, Garcia J, Davies T. 2012. Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study. International journal of antimicrobial agents;39(4):311-6.

14. Naas T, Ergani A, Carrer A, Nordmann P. 2011. Real-time PCR for detection of NDM-1 carbapenemase genes from spiked stool samples. Antimicrob Agents Chemother;55(9):4038-43.

15. Nijhuis R, Samuelsen O, Savelkoul P, van Zwet A. 2013. Evaluation of a new real-time PCR assay (Check-Direct CPE) for rapid detection of KPC, OXA-48, VIM, and NDM carbapenemases using spiked rectal swabs. Diagn Microbiol Infect Dis;77(4):316-20.

16. Okoche D, Asimwwe BB, Katabazi FA, Kato L, Najjuka CF. 2015. Prevalence and Characterization of Carbapenem-Resistant Enterobacteriaceae Isolated from Mulago National Referral Hospital, Uganda. PLoS One;10(8).
17. Oviano M, Torres I, Gonzalez M, Bou G. 2016. Evaluation of a novel procedure for rapid detection of carbapenemase-producing Enterobacteriaceae (CPE) using the LightMix(R) modular carbapenemase kits. J Antimicrob Chemother;26.

18. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. 2008. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infection control and hospital epidemiology;29(12):1099-106.

19. Pecora ND, Li N, Allard M, Li C, Albano E, Delaney M, Dubois A, Onderdonk AB, Bry L. 2015. Genomically Informed Surveillance for Carbapenem-Resistant Enterobacteriaceae in a Health Care System. MBio;6(4):01030-15.

20. Rajabnia R, Asgharpour F, Ferdosi Shahandashti E, Moulana Z. 2015. Nosocomial emerging of (VIM1) carbapenemase-producing isolates of Klebsiella pneumoniae in North of Iran. Iran J Microbiol;7(2):88-93.

21. Sahin K, Tekin A, Ozdas S, Akin D, Yapislar H, Dilek AR, Sonmez E. 2015. Evaluation of carbapenem resistance using phenotypic and genotypic techniques in Enterobacteriaceae isolates. Ann Clin Microbiol Antimicrob;14(44):015-0105.

22. Solanki R, Vanjari L, Subramanian S, B A, E N, Lakshmi V. 2014. Comparative Evaluation of Multiplex PCR and Routine Laboratory Phenotypic Methods for Detection of Carbapenemases among Gram Negative Bacilli. J Clin Diagn Res;8(12):5.

23. Souli M, Galani I, Antoniadou A, Papadomichelakis E, Poulakou G, Panagea T, Vourli S, Zerva L, Armaganidis A, Giamarellou H. 2010. An outbreak of infection due to beta-Lactamase Klebsiella pneumoniae Carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes. Clin Infect Dis;50(3):364-73.

24. van der Zee A, Roorda L, Bosman G, Fluit AC, Hermans M, Smits PH, van der Zanden AG, Te Witt R, Bruijnesteijn van Coppenraet LE, Cohen Stuart J, Ossewaarde JM. 2014. Multi-centre evaluation of real-time multiplex PCR for detection of carbapenemase genes OXA-48, VIM, IMP, NDM and KPC. BMC Infect Dis;14(27):1471-2334.

25. Villumsen S, Pedersen R, Krogfelt KA, Jensen JS. 2010. Expanding the diagnostic use of PCR in leptospirosis: improved method for DNA extraction from blood cultures. PloS one;5(8):e12095.

26. Wang JT, Wu UI, Lauderdale TL, Chen MC, Li SY, Hsu LY, Chang SC. 2015. Carbapenem-nonsusceptible Enterobacteriaceae in Taiwan. PLoS One;10(3).

27. Wang X, Chen G, Wu X, Wang L, Cai J, Chan EW, Chen S, Zhang R. 2015. Increased prevalence of carbapenem resistant Enterobacteriaceae in hospital setting due to cross-species transmission of the bla NDM-1 element and clonal spread of progenitor resistant strains. Front Microbiol;6(595).

28. Xu Y, Gu B, Huang M, Liu H, Xu T, Xia W, Wang T. 2015. Epidemiology of carbapenem resistant Enterobacteriaceae (CRE) during 2000-2012 in Asia. Journal of thoracic disease;7(3):376-85.
Table 1: The effectiveness of DNA extraction methods, M1 and M2 in recovering *blaNDM-1* carbapenamase-producing *Klebsiella pneumoniae*

| DNA-extraction method | Positive for *blaNDM-1* | Internal control (IC) amplification | Non-template control (NTC) amplification |
|-----------------------|-------------------------|-------------------------------------|----------------------------------------|
| **M1**                |                         |                                     |                                        |
| A1                    | +                       | +                                   | -                                      |
| A2                    | +                       | +                                   | -                                      |
| A3                    | +                       | +                                   | -                                      |
| **M2**                |                         |                                     |                                        |
| A1                    | +                       | +                                   | -                                      |
| A2                    | +                       | +                                   | -                                      |
| A3                    | +                       | +                                   | -                                      |

M1: Qiagen, DNeasy® Blood & Tissue Kit

M2: Macherey-Nachel, Nucleospin® Blood QuickPure